Clinical Trial Results:
A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled
Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg
BID, 5 mg BID and 10 mg QD Versus Placebo in Patients with Type 2
Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy
Summary
|
|
EudraCT number |
2010-019511-37 |
Trial protocol |
SK DE HU |
Global completion date |
01 Aug 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Sep 2016
|
First version publication date |
21 Sep 2016
|
Other versions |
|
Summary report(s) |
D1691C00003 full data set |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.